Summary
Cannot evaluate most claims against the supplied prescribing information because the provided label excerpts do not include the relevant warfarin monitoring guidance, INR definition, or bleeding-risk/interaction details for aspirin, clopidogrel, apixaban, or rivaroxaban.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
12.1 Mechanism of Action: LIPITOR described as an HMG-CoA reductase inhibitor (statin class implied by label section content).
Atorvastatin is an inhibitor of HMG-CoA reductase.
11 DESCRIPTION; 12.1 Mechanism of Action.
Unsupported Statements
Atorvastatin works by inhibiting the production of cholesterol in the liver.
Supported that it inhibits HMG-CoA reductase and is involved in cholesterol synthesis in liver, but the claim is over-specific that it 'inhibits production of cholesterol in the liver' as the sole mechanism; label discusses cholesterol synthesis and LDL clearance and also liver LDL receptor effects.
Atorvastatin can be taken with warfarin.
The provided label excerpt (7.7 Warfarin) states LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin. It does not explicitly state 'can be taken with warfarin.'
When atorvastatin is taken with warfarin, the international normalized ratio (INR) should be closely monitored.
The provided label excerpt only addresses prothrombin time effect and does not mention INR monitoring.
The INR is a measure of how long it takes blood to clot.
No INR definition is present in the supplied label excerpts.
The INR can be affected by the combination of Lipitor and warfarin.
Label excerpt says no clinically significant effect on prothrombin time; no statement about INR.
Taking Lipitor with aspirin may increase the risk of bleeding.
No aspirin-related bleeding-risk or interaction information is present in supplied excerpts.
The bleeding risk with Lipitor plus aspirin may be particularly increased in patients with a history of gastrointestinal bleeding.
No aspirin/GI-bleeding interaction or risk stratification present in supplied excerpts.
Combining Lipitor with clopidogrel may increase the risk of bleeding.
No clopidogrel-related bleeding-risk or interaction information is present in supplied excerpts.
The bleeding risk with Lipitor plus clopidogrel may be particularly increased in patients with a history of gastrointestinal bleeding.
No clopidogrel/GI-bleeding interaction or risk stratification present in supplied excerpts.
Taking Lipitor with apixaban may increase the risk of bleeding.
No apixaban-related bleeding-risk or interaction information is present in supplied excerpts.
The bleeding risk with Lipitor plus apixaban may be particularly increased in patients with a history of gastrointestinal bleeding.
No apixaban/GI-bleeding interaction or risk stratification present in supplied excerpts.
Taking Lipitor with rivaroxaban may increase the risk of bleeding.
No rivaroxaban-related bleeding-risk or interaction information is present in supplied excerpts.
The bleeding risk with Lipitor plus rivaroxaban may be particularly increased in patients with a history of gastrointestinal bleeding.
No rivaroxaban/GI-bleeding interaction or risk stratification present in supplied excerpts.
The combination of Lipitor and blood thinners can be safe.
The label excerpt does not provide a general statement about safety of 'blood thinners' broadly; only one interaction point for warfarin (prothrombin time).
When using the combination of Lipitor and blood thinners, it is essential to monitor the patient's INR and bleeding risk closely.
No INR monitoring or bleeding-risk monitoring guidance is present for these combinations in supplied excerpts.
Regularly checking INR levels is necessary to ensure they are within the target range.
No INR monitoring or target range language is present in supplied excerpts.
Patients should inform their healthcare provider immediately if they experience signs of bleeding such as bruising, nosebleeds, or gastrointestinal bleeding.
No bleeding symptom counseling guidance is present in supplied excerpts.
Adjusting the dose of Lipitor or blood thinners as needed may be necessary to minimize the risk of bleeding.
No dosing-adjustment guidance for bleeding risk with these drug combinations is present in supplied excerpts.
Contradictions
Low
AI Statement
When atorvastatin is taken with warfarin, the international normalized ratio (INR) should be closely monitored.
Label Reference
7.7 Warfarin: 'LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.'
Low
AI Statement
The INR can be affected by the combination of Lipitor and warfarin.
Label Reference
7.7 Warfarin: 'LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.'
Important Omissions
For warfarin specifically, the label excerpt provided does not support INR monitoring; it only states no clinically significant effect on prothrombin time. A safer label-aligned statement would reflect this nuance.
Importance:
Moderate
Bleeding-risk interaction statements for aspirin, clopidogrel, apixaban, and rivaroxaban are not present in the supplied excerpts; if the full label includes these, they are omitted from what was provided, preventing verification.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Multiple interaction/monitoring and bleeding-risk claims (INR monitoring and bleeding-risk increases across several antithrombotics) are unsupported by the supplied label excerpts; this could lead to incorrect clinical expectations and potentially inappropriate monitoring or reassurance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about INR monitoring and bleeding-risk with aspirin, clopidogrel, apixaban, and rivaroxaban are not supported by the supplied FDA label excerpts; warfarin-related claims conflict with the provided statement about no clinically significant effect on prothrombin time.
Suggested Improvement
Limit interaction statements to what the supplied label excerpts support (e.g., warfarin: no clinically significant effect on prothrombin time) and remove or verify (with the full label sections) any bleeding-risk/INR definitions and monitoring guidance for aspirin, clopidogrel, apixaban, and rivaroxaban.